Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A Nationwide Study: GEIH-Ab project (2000);Diversidad clonal y sensibilidad a los antimicrobianos de Acinetobacter baumannii aislados en hospitales españoles. Estudio Multicéntrico Nacional: Proyecto GEIH-Ab 2000

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 5, 2004, Pages 267-271

  Fernández Cuenca, Felipe ^a,f   Pascual, Alvaro ^a,b   Ribera, Anna ^c   Vila, Jordi ^c   Bou, Germán ^d   Cisneros, José Miguel ^e   Rodríguez Baño, Jesús ^b   Pachón, Jerónimo ^e   Martínez Martínez, Luis ^a,b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Acinetobacter baumannii; Antimicrobial susceptibility; Clonal diversity

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFALOTIN; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; GEMIFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; MINOCYCLINE; PIPERACILLIN; POLYMYXIN B; RIFAMPICIN; SULBACTAM; TETRACYCLINE; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLONAL VARIATION; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; RESTRICTION MAPPING; SPAIN;

EID: 2942528893     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13059819     Document Type: Article

References (26)

1. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogen: Microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148-65.
2. Bouvet PJM, Grimont PAD. Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobactern junii sp. nov. and emended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwoffii. Int J Syst Bacteriol 1986;36:228-40.
3. Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol 1991;29:277-82.
4. Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 1993;37:750-3.
5. García Arata MI, Alarcón T, López Brea M. Emergence of resistant isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex in a Spanish hospital over a five-year period. Eur J Clin Microbiol Infect Dis 1996; 15:512-5.
6. Picazo JJ, Betriu C, Rodríguez-Avial I, Azahares E, Ali Sánchez B, Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: estudio VIRA. Enferm Infecc Microbiol Clin 2002;20:503-10.
7. Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002;49:479-87.
8. Álvarez Lerma F, Montserrat Gasulla G, Abad Peruga V, Pueyo Pont MJ, Tarragó Eixarch E. Efectividad del aislamiento de contacto en el control de bacterias multirresistentes en un servicio de medicina intensiva. Enferm Infecc Microbiol Clin 2002;20:57-63.
9. Martínez Pellús A, Ruiz Gómez J, Jaime Sánchez F, Simarro Córdoba E, Fernández Lozano JA. Incidencia de colonización e infección de Acinetobacter baumannii en una UCI con situación de endemia. Análisis de factores de riesgo mediante un estudio de vigilancia. Enferm Infecc Microbiol Clin 2002;20:194-9.
10. Jiménez-Mejías ME, Pachón J, Becerril B, Palomino-Nicas J, Rodríguez-Cobacho A, Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997;4:932-5.
11. Rodríguez Hernández MJ, Pachón J, Pichardo C, Ibáñez Martínez J, García Curiel A, Caballero FJ, et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 2000;45:493-501.
12. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, et al. Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46:1946-52.
13. Reina J. Sensibilidad de Acinetobacter calcoaceticus-baumannii complex y Acinetobacter lwoffii a los antibióticos de uso clínico. Rev Enf Infec Micr Clin 1991;9:438-9.
14. Vila J, Marcos A, Marco F, Abdalla S, Vergara Y, Reig R, et al. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993;37: 138-41.
15. Echeverría JM, López de Goicoechea MJ, Ayarza R, Vecino Y, Lazpita MA, Ibarretxebea AB, et al. Actividad in vitro de 9 antibióticos y 3 inhibidores de beta-lactamasas frente a 107 aislamientos clínicos de Acinetobacter baumannii. Enferm Infecc Microbiol Clin 1997;15:319-22.
16. López Hernández S, Alarcón T, López Brea M. Evolución de la sensibilidad antimicrobiana en aislamientos clínicos de Acinetobacter baumannii (1995-1997). Rev Esp Quimioterap 2000;394-400.
17. Vaneechoutte M, Dijkshoorn L, Tjernberg I, Elaichouni A, De Vos P, Caléis G, et al. Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J Clin Microbiol 1995;33:11-5.
18. Allardet Servent A, Bouzigues N, Carles Nurit MJ, Bourg G, Gouby A, Ramuz M. Use of low-frequency-cleavage- restriction endonuclease for DNA analysis in epidemiological investigations of nosocomial bacterial infections. J Clin Microbiol 1989;27:2057-61.
19. Tenover FC, Arbeit RD, Goering RV, Mickelsen BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-9.
20. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacterial that Grow Aerobically. Approved Standard M7-A5. Wayne PA, NCCLS, 2000.
21. Members of the SFM Antibiogram Committee. Comité de l'Antibiogramme de la Société Fraņaise de Microbiologie Report 2003. Int J Antimicrob Agents 2003;21:364-91.
22. Dijkshoorn L, Aucken H, Gerner-Smidt P, Janssen P, Kaufmann ME, Garaizar J, et al. Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J Clin Microbiol 1996; 34:1519-25.
23. Vila J, Ruiz J, Navia M, Becerril B, García I, Perea S, et al. Spread of amikacin resistance in Acinetobacter baumannii strains isolated in Spain due to an epidemic strain. J Clin Microbiol 1999;37:758-61.
24. Villari P, Iacuzio L, Vozzella EA, Bosco U. Unusual genetic heterogeneity of Acinetobacter baumannii isolates in a university hospital in Italy. Am J Infect Control 1999;27:247-53.
25. Rodríguez Baño J. Nosocomial bacteriemia due to Acinetobacter baumannii. Rev Med Microbiol 1999;10:67-77.
26. Villers D, Espace E, Coste-Burel M, Gianffret F, Ninin E, Nicolas F, et al. Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med 1998;129:182-9.